Sign up
Pharma Capital

Clinigen boss hails launch of breast cancer drug Halaven in important South African market

CEO of Clinigen PLC (LON:CLIN) Shaun Chilton talks to Proactive about the UK Pharma group making the breast cancer drug Halaven (eribulin) available in South Africa for the first time for women in an advanced stage of the disease.


View full CLIN profile View Profile
View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.